# A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).

> **NCT00760929** · PHASE2 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 171 (actual)

## Conditions studied

- Non-Squamous Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Placebo
- **DRUG:** Placebo
- **DRUG:** RG1507
- **DRUG:** RG1507
- **DRUG:** erlotinib [Tarceva]

## Key facts

- **NCT ID:** NCT00760929
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-11-10
- **Primary completion:** 2010-06-25
- **Final completion:** 2010-06-25
- **Target enrollment:** 171 (ACTUAL)
- **Why stopped:** The study was terminated due to the termination of the clinical development program.
- **Last updated:** 2021-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00760929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00760929, "A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00760929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*